DE3872878D1 - Behandlung von diabetes durch kombinierte insulinformen. - Google Patents

Behandlung von diabetes durch kombinierte insulinformen.

Info

Publication number
DE3872878D1
DE3872878D1 DE8888904864T DE3872878T DE3872878D1 DE 3872878 D1 DE3872878 D1 DE 3872878D1 DE 8888904864 T DE8888904864 T DE 8888904864T DE 3872878 T DE3872878 T DE 3872878T DE 3872878 D1 DE3872878 D1 DE 3872878D1
Authority
DE
Germany
Prior art keywords
insulin
function
liver
targeted
encapsulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8888904864T
Other languages
English (en)
Other versions
DE3872878T2 (de
Inventor
Walter Blair Geho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SDG Inc
Original Assignee
Technology Unlimited Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technology Unlimited Inc filed Critical Technology Unlimited Inc
Publication of DE3872878D1 publication Critical patent/DE3872878D1/de
Application granted granted Critical
Publication of DE3872878T2 publication Critical patent/DE3872878T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Birds (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE8888904864T 1988-01-13 1988-05-13 Behandlung von diabetes durch kombinierte insulinformen. Expired - Lifetime DE3872878T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/143,180 US4863896A (en) 1984-05-03 1988-01-13 Diabetic control by combined insulin forms
PCT/US1988/001536 WO1989006540A1 (en) 1988-01-13 1988-05-13 Diabetic control by combined insulin forms

Publications (2)

Publication Number Publication Date
DE3872878D1 true DE3872878D1 (de) 1992-08-20
DE3872878T2 DE3872878T2 (de) 1992-12-03

Family

ID=22502938

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8888904864T Expired - Lifetime DE3872878T2 (de) 1988-01-13 1988-05-13 Behandlung von diabetes durch kombinierte insulinformen.

Country Status (8)

Country Link
US (1) US4863896A (de)
EP (1) EP0358709B1 (de)
AT (1) ATE78169T1 (de)
AU (1) AU622370B2 (de)
DE (1) DE3872878T2 (de)
DK (1) DK452289A (de)
FI (1) FI894376A0 (de)
WO (1) WO1989006540A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420108A (en) * 1992-09-14 1995-05-30 Shohet; Isaac H. Method of controlling diabetes mellitus
WO1999016425A1 (en) * 1997-09-30 1999-04-08 The Ohio State University Lipid-modified insulin incorporated liposomes for selectively delivering cytotoxic agents to hepatoma cells
US7169410B1 (en) * 1998-05-19 2007-01-30 Sdg, Inc. Targeted liposomal drug delivery system
US6159931A (en) * 1998-09-29 2000-12-12 The Ohio State University Lipid-modified insulin incorporated liposomes for selectively delivering cytotoxic agents to hepatoma cells
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
AU2003236521A1 (en) * 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
JP5452843B2 (ja) 2003-01-06 2014-03-26 エミスフィアー テクノロジーズ インコーポレイテッド 夜間の経口インスリン治療
US20050203001A1 (en) 2004-03-05 2005-09-15 Emisphere Technologies, Inc. Oral insulin therapies and protocol
WO2005053605A2 (en) * 2003-09-09 2005-06-16 Gilead Sciences, Inc. Therapeutic liposomes
US7605123B2 (en) 2004-07-19 2009-10-20 Biocon Ltd. Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof
US20110135725A1 (en) 2005-05-23 2011-06-09 Sdg, Inc. Lipid Construct for Delivery of Insulin to a Mammal
WO2006127361A2 (en) 2005-05-23 2006-11-30 Sdg, Inc. Lipid construct for delivery of insulin to a mammal
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
JP5868594B2 (ja) 2007-10-16 2016-02-24 バイオコン・リミテッドＢｉｏｃｏｎ Ｌｉｍｉｔｅｄ 経口投与可能な固形医薬組成物及びそのプロセス
US20120035105A1 (en) * 2009-01-09 2012-02-09 Sdg, Inc. Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments
AU2010208381A1 (en) 2009-01-28 2011-08-04 Smartcells, Inc. Exogenously triggered controlled release materials and uses thereof
WO2010088286A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
US8906850B2 (en) 2009-01-28 2014-12-09 Smartcells, Inc. Crystalline insulin-conjugates
KR20110104081A (ko) 2009-01-28 2011-09-21 스마트쎌스, 인크. 제어 약물 전달을 위한 접합체 기재 시스템
WO2010107519A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
WO2010107520A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
EP2598522A4 (de) 2010-07-28 2014-11-12 Smartcells Inc Rekombinante lektine, bindungsstellenmodifizierte lektine und anwendungen davon
WO2012015681A2 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
US9074015B2 (en) 2010-07-28 2015-07-07 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
US9884125B2 (en) 2013-10-04 2018-02-06 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
US20210137838A1 (en) 2017-03-13 2021-05-13 Sdg, Inc. Lipid-based nanoparticles with enhanced stability
US11077173B2 (en) 2017-03-13 2021-08-03 Sdg, Inc. Lipid-based nanoparticles and methods using same
AU2020271901A1 (en) * 2019-04-12 2021-11-04 Sdg, Inc. Lipid-based nanoparticles and use of same in optimized insulin dosing regimens

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377567A (en) * 1978-10-02 1983-03-22 The Procter & Gamble Company Lipid membrane drug delivery
US4603044A (en) * 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system

Also Published As

Publication number Publication date
DK452289D0 (da) 1989-09-13
WO1989006540A1 (en) 1989-07-27
EP0358709A1 (de) 1990-03-21
EP0358709B1 (de) 1992-07-15
FI894376A0 (fi) 1989-09-15
US4863896A (en) 1989-09-05
ATE78169T1 (de) 1992-08-15
AU622370B2 (en) 1992-04-02
AU1790588A (en) 1989-08-11
EP0358709A4 (de) 1990-03-08
DK452289A (da) 1989-11-09
DE3872878T2 (de) 1992-12-03

Similar Documents

Publication Publication Date Title
DE3872878D1 (de) Behandlung von diabetes durch kombinierte insulinformen.
DK0527835T3 (da) Doseringsform til afgivelse af et anti-Parkinsonmiddel
DE69010336D1 (de) Pharmazeutische zusammensetzung zum abnehmen.
GEP20002146B (en) Therapeutic Peptide Derivatives
ES2060941T3 (es) Uso de nicotina para la fabricacion de un estuche para el tratamiento de condiciones susceptibles de dicho tratamiento.
SE8204874D0 (sv) Farmaceutiska preparat, innefattande humant insulin och humant proinsulin
KR910005858A (ko) 지방산 요법
MY105798A (en) Treatment of leukocyte dysfunction with gm-csf.
KR100271087B1 (en) Protein synthesis stimulator comprising tcf-2 for the treatment of hypoproteinemia
PT651654E (pt) Utilizacao de um dimero de lisozima para a preparacao de um medicamento para modular os mecanismos natutais de defesa
AR003979A1 (es) Administracion transdermica de vorozol.
Rosenthal Alterations in serum thyroxine with cerebral electrotherapy (electrosleep)
AR029160A1 (es) El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo
Katoh et al. Intraarterial lymphocytes injection for treatment of lymphedema
DK1007085T3 (da) Anvendelse af væksthormon i præparater til behandling af insulin-resistens i hjertet
AR008155A1 (es) Uso de un compuesto de formula i para preparar un medicamento util para tratar y prevenir la enfermedad cardiovascular post menopausica en mujeres.
SE9101341D0 (sv) New medicinal use
GB2019720A (en) S-adenosyl-L-homocysteine and salts thereof for use in therapy
RU2076724C1 (ru) Способ лечения радиационных поражений
JPS6016921A (ja) 貼付薬
ATE328604T1 (de) Verwendung von wachstumshormon in niederen dosen
RU94020918A (ru) Способ лечения опсоменореи
RU94006632A (ru) Способ лечения неспецифического язвенного колита
邬亦贤 et al. THERAPEUTIC EFFECT AND MECHANISM OF ACUPUNCTURE AT NEIGUAN (P. 6) IN CHRONIC RHEUMATIC HEART DISEASE
徐济民 et al. ANTIARRHYTHMIC ACTION OF CHANGROLIN ADMINISTERED BY CONTINUOUS INTRAVENOUS INFUSION

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SDG, INC., WOOSTER, OHIO, US

8328 Change in the person/name/address of the agent

Free format text: TIEDTKE, BUEHLING, KINNE & PARTNER, 80336 MUENCHEN

8339 Ceased/non-payment of the annual fee